Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 4, 1999, Pages 211-216

  Keeffe, Emmet B ^a   Dusheiko, Geoffrey M ^b   Tong, Myron J ^c   Hollinger, F Blaine ^d   Heathcote, E Jenny L ^g   McHutchison, John ^e   Albert, Donald ^f  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c HUNTINGTON MEMORIAL HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e SCRIPPS CLINIC   (United States)

^f AMGEN INC   (United States)

^g NONE

Author keywords

Genotype; HCV; Hepatitis C; Interferon

Indexed keywords

ALPHA2B INTERFERON; CONSENSUS INTERFERON; INTERFERON; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; RNA, VIRAL;

EID: 0033498630     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Simmonds P, Rose KA, Graham S et al, Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infection with HCV types 1,2, and 3. J Clin Microbiol (1993) 31: 1493-503.
2. Simmonds P, Alberti A, Alter HJ et al, A proposed system for nomenclature of genotypes for hepatitis C virus. Hepatology (1994) 19: 1321-4.
3. Forns X, Bukh J, The molecular biology of hepatitis C viruses: genotypes and quasispecies. Clin Liver Dis (1999) 3: 693-716.
4. Davis G, Lau J, Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology (1997) 26(Suppl 1): 112S-27S.
5. Barnes E, Webster G, Whalley S, Dusheiko G, Predictors of a favorable response to alpha interferon therapy for hepatitis C. Clin Liver Dis (1999) 3: 775-91.
6. Poynard T, Marcellin P, Lee SS et al, Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet (1998) 352: 1426-32.
7. McHutchison JG, Gordon SC, Schiff ER, et al, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med (1998) 339: 1485-92.
8. Kohara M, Tanaka T, Tsukiyama-Kohara K et al, Hepatitis C virus genotypes 1 and 2 respond to interferon-alpha with different virologic kinetics. J Infect Dis (1995) 172: 934-93.
9. Lee WM, Reddy KR, Tong MJ et al. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology (1998) 28: 1411-15.
10. Tong M, Reddy KR, Lee WM et al, Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology (1997) 26: 747-54.
11. Simmonds P, Smith DB, McOmish F et al, Identification of genotypes of hepatitis C virus by sequence comparison in the core, E1 and NS-5 regions. J Gen Virol (1994) 75: 1053-61.
12. Stuyver L, Rossau R, Wyseur A et al, Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol (1993) 74: 1093-102.